LLY

1,015.54

-1.12%↓

JNJ

242.2

-1.01%↓

ABBV

224.89

-0.91%↓

NVS

165.61

-0.93%↓

MRK

119.59

-2.33%↓

LLY

1,015.54

-1.12%↓

JNJ

242.2

-1.01%↓

ABBV

224.89

-0.91%↓

NVS

165.61

-0.93%↓

MRK

119.59

-2.33%↓

LLY

1,015.54

-1.12%↓

JNJ

242.2

-1.01%↓

ABBV

224.89

-0.91%↓

NVS

165.61

-0.93%↓

MRK

119.59

-2.33%↓

LLY

1,015.54

-1.12%↓

JNJ

242.2

-1.01%↓

ABBV

224.89

-0.91%↓

NVS

165.61

-0.93%↓

MRK

119.59

-2.33%↓

LLY

1,015.54

-1.12%↓

JNJ

242.2

-1.01%↓

ABBV

224.89

-0.91%↓

NVS

165.61

-0.93%↓

MRK

119.59

-2.33%↓

Search

Integra LifeSciences Holdings Corp

Atvērts

SektorsVeselības aprūpe

11.18 -2.78

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

10.58

Max

11.64

Galvenie mērījumi

By Trading Economics

Ienākumi

479M

-5.4M

Pārdošana

-14M

402M

Peļņas marža

-1.344

Darbinieki

4,396

EBITDA

526M

54M

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

+12.17% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 26. febr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-340M

916M

Iepriekšējā atvēršanas cena

13.96

Iepriekšējā slēgšanas cena

11.18

Ziņu noskaņojums

By Acuity

50%

50%

167 / 351 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

Integra LifeSciences Holdings Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 25. febr. 23:25 UTC

Karstas akcijas

Stocks to Watch: C3.ai, Salesforce, Pure Storage, Zoom

2026. g. 25. febr. 23:15 UTC

Peļņas

Salesforce Sees Stable Growth; CEO Dismisses Talk of AI-Fueled 'SaaS-Pocalypse' -- 2nd Update

2026. g. 25. febr. 23:54 UTC

Tirgus saruna

Gold Steady Ahead of U.S.-Iran Talks -- Market Talk

2026. g. 25. febr. 23:47 UTC

Peļņas

Ferrovial 4Q Net EUR197M >FER.MC

2026. g. 25. febr. 23:45 UTC

Peļņas

Ferrovial 4Q Rev EUR2.72B >FER.MC

2026. g. 25. febr. 23:42 UTC

Peļņas

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 4th Update

2026. g. 25. febr. 23:38 UTC

Tirgus saruna

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com: Company's Business Operations Remain Normal >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com Gives Update on Investigation by China's State Administration for Market Regulation >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com: Cannot Predict Status or Results of Investigation, Will Provide Updates on Conclusion >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com Increase in FY Profit Primarily Due to Gain From Investments >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com Will Continue to Communicate With SAMR on Compliance With Regulatory Requirements >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com: SAMR Investigation Related to China's Anti-monopoly Law >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com: Investigation Ongoing, Company Is Cooperating With SAMR >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com Co-founders Min Fan, Qi Ji Resign From Positions >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com: Fan Resigned as Director and President; Ji Resigned as a Director >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com FY Rev CNY62.4B, Up 17% >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com FY Net CNY33.3B Vs. Net CNY17.1B >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com FY EPS CNY47.67 >TCOM

2026. g. 25. febr. 23:06 UTC

Peļņas

Correction to Nvidia Fourth Quarter Results Article -- WSJ

2026. g. 25. febr. 23:01 UTC

Peļņas

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 3rd Update

2026. g. 25. febr. 23:00 UTC

Tirgus saruna
Peļņas

Global Equities Roundup: Market Talk

2026. g. 25. febr. 23:00 UTC

Tirgus saruna
Peļņas

Nvidia: Chinese Competitors Pose Risk to U.S. Dominance in AI -- Market Talk

2026. g. 25. febr. 22:56 UTC

Tirgus saruna
Peļņas

Nvidia CEO Says Customers Can't Grow Revenue Without Compute -- Market Talk

2026. g. 25. febr. 22:43 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Paramount Streaming Revenue Rises, but TV Segment Faces Headwinds -- WSJ

2026. g. 25. febr. 22:40 UTC

Tirgus saruna
Peļņas

Nvidia Says Agentic AI Has Reached Inflection Point -- Market Talk

2026. g. 25. febr. 22:40 UTC

Peļņas

Karoon Energy Says Search for New CFO Well Advanced

2026. g. 25. febr. 22:39 UTC

Peļņas

Karoon Energy Says CFO Ray Church to Leave Company

2026. g. 25. febr. 22:39 UTC

Peļņas

Karoon Energy Says On-Market Share Buyback Program Ongoing at Moderated Level

2026. g. 25. febr. 22:38 UTC

Peļņas

Karoon Energy Says Guidance for 2026 Key Metrics Unchanged

Salīdzinājums

Cenas izmaiņa

Integra LifeSciences Holdings Corp Prognoze

Cenas mērķis

By TipRanks

12.17% augšup

Prognoze 12 mēnešiem

Vidējais 13 USD  12.17%

Augstākais 13 USD

Zemākais 13 USD

Pamatojoties uz 2 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Integra LifeSciences Holdings Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

2 ratings

0

Pirkt

2

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

12.75 / 16.41Atbalsts un pretestība

Īstermiņā

Strong Bearish Evidence

Vidējā termiņā

Strong Bearish Evidence

Ilgtermiņā

Weak Bearish Evidence

Noskaņojums

By Acuity

167 / 351 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Integra LifeSciences Holdings Corp

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
help-icon Live chat